Why GLP-1 drugs slow gastric emptying, and whether it drives appetite

GLP-1 receptor agonists slow the rate at which the stomach empties, and a 2026 meta-analysis put the average delay at 74 minutes. Whether that slowing is what reduces appetite is a separate question, and the best appetite analysis we found says it explains very little. This article keeps those two claims apart and sets out what the evidence can and cannot support.

What does GLP-1 do to the stomach?

The natural hormone is secreted by intestinal L-cells in response to a meal. Holst's 2007 review in Physiological Reviews lists its effects on the gut: GLP-1 inhibits gastrointestinal motility and secretion, which makes it an enterogastrone and part of the 'ileal brake' mechanism. The semaglutide and liraglutide molecules are GLP-1 receptor agonists, so the slowing is expected to appear with them, and the question is how large it is.

How large is the delay?

Chen and colleagues searched six databases for prospective studies that measured gastric emptying half-time with and without GLP-1 receptor agonist treatment. They pooled 10 studies with 300 participants, one of which contributed two independent samples. The pooled effect was large, with a standardized mean difference of 2.38, corresponding to a mean prolongation of 74 minutes (95% CI, 46 to 101). The authors grade the certainty of that estimate as very low, so the figure is a useful rough size rather than a settled number.

The short-acting subgroup showed a trend toward a larger effect, but its confidence interval is wide. The early-treatment figure, 82 minutes, sits close to the pooled estimate, so this analysis does not show whether the delay fades with longer use. Those are the gaps the authors leave open.

Does a slower stomach reduce appetite?

The most direct test we found is a secondary analysis by Friedman, Harmsen and Camilleri in Obesity. It used data from a 16-week, randomized, placebo-controlled liraglutide trial in people with obesity (ClinicalTrials.gov NCT02647944). The authors correlated solid-food gastric emptying with measures of satiation and energy intake. Across the combined cohorts at baseline and at the end of treatment, emptying correlated with energy intake and, at baseline, with one satiation measure. Gastric emptying accounted for only 4% to 6% of the variance in those appetite measures.

The correlation did not hold inside either treatment group when analyzed alone. Participants who showed normal, persistently delayed or transiently delayed emptying during liraglutide treatment did not differ in appetite measures. The authors conclude that delayed gastric emptying 'appears to play little direct role' in liraglutide-induced appetite suppression. That is a strong finding for one drug, but it is a secondary analysis of one 16-week trial, and a correlation share cannot rule out an indirect role. The authors themselves call for work on whether other GLP-1 receptor agonists act on appetite through emptying or through other gastrointestinal effects.

Why does the slowing matter beyond appetite?

The gastric effect has practical consequences that do not depend on appetite. The 2026 narrative review by Singhani and colleagues reports that nausea, vomiting, diarrhea and constipation are established class effects, occurring in roughly 30% to 50% of patients, typically during initiation and dose escalation. The mechanisms it lists include delayed gastric emptying, central activation of emetic pathways, altered intestinal motility and the physiology of rapid weight loss. The same review reports increased residual gastric volume in peri-procedural data, without confirmed aspiration events.

That residual-volume finding is the reason anesthesia teams pay attention to these drugs. The 2025 SPAQI consensus statement, built on a modified Delphi process and a systematic review, sets out perioperative recommendations for GLP-1 receptor agonist users, including fasting times. The abstract we opened does not list the recommendations, so we do not quote them here. Anyone with a planned procedure should follow the instructions of their own anesthesia team.

What is still unknown

Three things remain open. The pooled estimate rests on prospective studies with very low certainty, and the meta-analysis does not separate every drug. The appetite analysis covers one drug in one trial. And the sources we opened do not establish whether the emptying delay changes over months of treatment, since the early-treatment estimate covers only the first 10 weeks.

What this means for research-grade material

Approved prescription products containing semaglutide and liraglutide exist. Research-grade material is not the approved product, and it is not the product studied in the trials discussed above. Anyone seeking treatment for obesity should speak to a physician about approved options. A physician can also weigh gastric and procedural risks, which a mechanism article cannot assess for an individual.

Bottom line

The pooled studies point to a substantial slowing of gastric emptying with GLP-1 receptor agonists, averaging about an hour, though the certainty of that estimate is very low. The best appetite analysis we found attributes only 4% to 6% of variance to that slowing, so emptying is unlikely to be the main appetite mechanism for liraglutide. For the receptor background, read our incretin biology article. For compound detail, see the semaglutide profile and the liraglutide profile.